Showing results (51-60 of 175) with videos related to

Sort By:
Pageof 18
Rheumatology Advances in Practice|February 28, 2024
Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept responsePhilippa D K Curry, Andrew P Morris, Meghna Jani, et al.
BMJ Case Reports|February 14, 2018
Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumabMatthew Js Parker, Mark E Roberts, Paul C Lorigan, et al.
Clinical and Experimental Rheumatology|February 28, 2022
The role of protein aggregation in the pathogenesis of inclusion body myositisAndrew M Snedden, Katherine A B Kellett, James B Lilleker, et al.
BMC Rheumatology|June 13, 2020
MicroRNA and mRNA profiling in the idiopathic inflammatory myopathiesJoanna E Parkes, Anastasia Thoma, Adam P Lightfoot, et al.
Nature Reviews. Rheumatology|October 6, 2023
Epidemiology of the idiopathic inflammatory myopathiesThomas Khoo, James B Lilleker, Bernard Yu-Hor Thong, et al.
Clinical and Experimental Rheumatology|June 1, 2016
Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferencesSarah Tansley, Gavin Shaddick, Lisa Christopher-Stine, et al.
Rheumatology (Oxford, England)|September 1, 2016
A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practiceMeghna Jani, Sean Gavan, Hector Chinoy, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 15, 2026
Urate-lowering effects of losartan: a meta-analysis of randomised controlled trials and target trial emulationXiaoguang Xu, Ahlam Naeem, Amber Emmett, et al.
Rheumatology (Oxford, England)|April 16, 2026
Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathwaysNahdia Afiifah Abdul Jalil, Hector Chinoy, Meghna Jani, et al.
Rheumatology (Oxford, England)|December 9, 2023
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritisPhilippa D K Curry, Ryan M Hum, Andrew P Morris, et al.
Pageof 18